150 related articles for article (PubMed ID: 37247272)
1. Clinical Exome Gene Panel Analysis of a Cohort of Urothelial Bladder Cancer Patients from Sri Lanka.
Malalasekera A; Neththikumara N; Somasundaram P; Pathirana S; Ediriweera C; Ediriweera D; Goonewardena SA; Perera ND; Abeygunasekara A; Jayasekara RW; Wettasinghe K; Lokuhetty MDS; Dissanayeke VHW
Asian Pac J Cancer Prev; 2023 May; 24(5):1533-1542. PubMed ID: 37247272
[TBL] [Abstract][Full Text] [Related]
2. Clinico-pathological characteristics and outcome of upper urinary tract urothelial carcinoma presenting to a tertiary care urology unit in Sri Lanka.
Jayarajah U; Fernando MH; Herath KB; Kuruppu SN; Wickramanayaka UL; Fernando IU; de Silva VC; Goonewardena SAS
Ceylon Med J; 2018 Sep; 63(3):129-132. PubMed ID: 30415517
[TBL] [Abstract][Full Text] [Related]
3. Bladder cancer in Sri Lanka: experience from a tertiary referral center.
Goonewardena SA; De Silva WA; De Silva MV
Int J Urol; 2004 Nov; 11(11):969-72. PubMed ID: 15509199
[TBL] [Abstract][Full Text] [Related]
4. Predicting progression of bladder urothelial carcinoma using microRNA expression.
Rosenberg E; Baniel J; Spector Y; Faerman A; Meiri E; Aharonov R; Margel D; Goren Y; Nativ O
BJU Int; 2013 Nov; 112(7):1027-34. PubMed ID: 23387295
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological patterns and outcomes of urothelial bladder malignancies in Sri Lankan patients.
Jayarajah U; Fernando H; Herath K; Kuruppu S; Wickramanayaka U; Fernando I; De Silva C; Goonewardena S
Ceylon Med J; 2020 Dec; 65(4):105-111. PubMed ID: 34821489
[TBL] [Abstract][Full Text] [Related]
6. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
[TBL] [Abstract][Full Text] [Related]
8. Chromatin-regulatory genes served as potential therapeutic targets for patients with urothelial bladder carcinoma.
Qiu JG; Shi DY; Liu X; Zheng XX; Wang L; Li Q
J Cell Physiol; 2019 May; 234(5):6976-6982. PubMed ID: 30317582
[TBL] [Abstract][Full Text] [Related]
9. Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.
Isharwal S; Hu W; Sarungbam J; Chen YB; Gopalan A; Fine SW; Tickoo SK; Sirintrapun SJ; Jadallah S; Loo FL; Pietzak EJ; Cha EK; Bochner BH; Berger MF; Iyer G; Solit DB; Reuter VE; Al-Ahmadie H
J Pathol; 2019 Jul; 248(3):260-265. PubMed ID: 30838648
[TBL] [Abstract][Full Text] [Related]
10. Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients.
Gerald T; Margulis V; Meng X; Bagrodia A; Cole S; Qin Q; Call SG; Mauer E; Lotan Y; Woldu SL
Urol Oncol; 2023 Mar; 41(3):148.e17-148.e24. PubMed ID: 36653279
[TBL] [Abstract][Full Text] [Related]
11. Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma.
Eich ML; Rodriguez Pena MDC; Springer SU; Taheri D; Tregnago AC; Salles DC; Bezerra SM; Cunha IW; Fujita K; Ertoy D; Bivalacqua TJ; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Netto GJ
Mod Pathol; 2019 Oct; 32(10):1544-1550. PubMed ID: 31028363
[TBL] [Abstract][Full Text] [Related]
12. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C
J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772
[TBL] [Abstract][Full Text] [Related]
13. Study of mutated p53 protein by immunohistochemistry in urothelial neoplasm of urinary bladder.
Roychowdhury A; Dey RK; Bandyapadhyay A; Bhattacharya P; Mitra RB; Dutta R
J Indian Med Assoc; 2012 Jun; 110(6):393-6. PubMed ID: 23360043
[TBL] [Abstract][Full Text] [Related]
14. Whole-exome sequencing identified mutational profiles of urothelial carcinoma post kidney transplantation.
Lim LM; Chung WY; Hwang DY; Yu CC; Ke HL; Liang PI; Lin TW; Cheng SM; Huang AM; Kuo HT
J Transl Med; 2022 Jul; 20(1):324. PubMed ID: 35864526
[TBL] [Abstract][Full Text] [Related]
15. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
Voutsadakis IA
Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
[No Abstract] [Full Text] [Related]
16. Frequent FGFR3 mutations in urothelial papilloma.
van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH
J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885
[TBL] [Abstract][Full Text] [Related]
17. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.
Yang K; Yu W; Liu H; Ding F; Zhang Y; Zhang Y; Wang W; Lou F; Cao S; Wang H; He Z
Oncologist; 2021 Aug; 26(8):e1395-e1405. PubMed ID: 34050578
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor receptor 3 gene (FGFR3) mutations in high-grade muscle-invasive urothelial bladder cancer in a Brazilian population: evaluation and prevalence.
Monteiro CRA; Korkes F; Krutman-Zveibil D; Glina S
Einstein (Sao Paulo); 2022; 20():eAO6450. PubMed ID: 35384983
[TBL] [Abstract][Full Text] [Related]
20. MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.
Olsson H; Hultman P; Rosell J; Söderkvist P; Jahnson S
BMC Urol; 2013 Jan; 13():5. PubMed ID: 23356517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
